BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

If we take a look at Pfizer’s top products for 2024, we can observe that the sales from their COVID vaccine, Comirnaty, dropped more than 50% vs. 2023 due to a decrease in vaccinations globally ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine was viable.

Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to ...

Pfizer said it anticipates no major vaccine policy changes under Trump in 2025. CEO Albert Bourla expressed willingness to work with RFK Jr. if confirmed to run the Department of Health and Human ...

Vaccine Development Insights Scientific Foundation Moderna and Pfizer-BioNTech vaccines are revolutionary in the field of immunology, utilizing messenger RNA (mRNA) technology to instruct cells to ...

The arrival of updated Pfizer-BioNTech and Moderna vaccines for the KP.2 variant comes well into a summer wave when Americans have struggled to find an existing shot.

The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...